Loading
TPT1 (Translationally-controlled tumour protein) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
Involved in calcium binding and microtubule stabilisation. Acts as a negative regulator of TSC22D1-mediated apoptosis, via interaction with and destabilisation of TSC22D1 protein.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Sertraline.
In plain words · TPT1 (Translationally-controlled tumour protein) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
TPT1 (Translationally-controlled tumour protein) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
Involved in calcium binding and microtubule stabilisation. Acts as a negative regulator of TSC22D1-mediated apoptosis, via interaction with and destabilisation of TSC22D1 protein.
No product in this corpus aims at TPT1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists TPT1 among essential proteins; a medicine acting on the wild-type protein would expose normal tissue too. HPA TPT1: RNA tissue enhanced (skeletal muscle 21,778 nTPM); no normal tissue stained high; highest cancer staining colorectal cancer (3 of 10 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas TPT1 tissue; Open Targets ENSG00000133112 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Gross et al, Nucleic Acids Res, 1989, "cDNA sequence coding for a translationally controlled human tumor protein". Source.
Sources: HGNC HGNC:12022 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P13693 (protein name, function text, keywords and locations (REST API)); CIViC gene TPT1 (1 evidence items, 0 assertions, 1 variants; diseases: Melanoma (GraphQL API, CC0))
Involved in calcium binding and microtubule stabilisation. Acts as a negative regulator of TSC22D1-mediated apoptosis, via interaction with and destabilisation of TSC22D1 protein. Location: Cytoplasm (UniProt). Locus 13q14.13 (HGNC).
RNA: tissue enhanced (skeletal muscle 21,778 nTPM), detected in all normal tissues.
No normal tissue stained high; medium in Appendix, Bone marrow, Bronchus, Cerebellum, Cerebral cortex, Cervix and more.
Medium only: breast cancer, cervical cancer, head and neck cancer, liver cancer.
HPA TPT1 tissue · HPA TPT1 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TPT1" OR ABSTRACT:"TPT1" OR TITLE:"tumor protein, translationally-controlled 1" OR ABSTRACT:"tumor protein, translationally-controlled 1" OR TITLE:"Translationally-controlled tumor protein" OR ABSTRACT:"Translationally-controlled tumor protein" OR TITLE:"fortilin" OR ABSTRACT:"fortilin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TPT1, not a curated reading list.